These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37748729)

  • 21. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?
    Jordan G; Staack RF
    Bioanalysis; 2020 Jul; 12(14):1021-1031. PubMed ID: 32633539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
    Wyant T; Yang L; Rosario M
    AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies.
    Niimi S; Nishimiya K; Nishidate M; Saito T; Minoura K; Kadotsuji K; Shimakura J; Shigemizu H; Hosogi J; Adachi M; Hashimoto T; Mori T; Harada H; Yamamoto KI; Nakamura T; Nomura T; Yamaguchi I; Sonehara K; Ishii-Watabe A; Kawasaki N
    Drug Metab Pharmacokinet; 2018 Apr; 33(2):125-132. PubMed ID: 29610053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
    Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
    AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size consideration for immunoassay screening cut-point determination.
    Zhang J; Zhang L; Yang H
    J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-drug Antibody Validation Testing and Reporting Harmonization.
    Myler H; Pedras-Vasconcelos J; Phillips K; Hottenstein CS; Chamberlain P; Devanaryan V; Gleason C; Goodman J; Manning MS; Purushothama S; Richards S; Shen H; Zoghbi J; Amaravadi L; Barger T; Bowen S; Bowsher RR; Clements-Egan A; Geng D; Goletz TJ; Gunn GR; Hallett W; Hodsdon ME; Janelsins BM; Jawa V; Kamondi S; Kirshner S; Kramer D; Liang M; Lindley K; Liu S; Liu Z; McNally J; Mikulskis A; Nelson R; Ahbari MR; Qu Q; Ruppel J; Snoeck V; Song A; Yan H; Ware M
    AAPS J; 2021 Dec; 24(1):4. PubMed ID: 34853961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
    Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
    J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Highly Specific Anti-drug Antibody Assay in Support of a Nanoparticle-based Therapeutic.
    Wang Y; Smith JF; Araya MM; Liao KK; Gorovits B
    AAPS J; 2020 Jun; 22(4):81. PubMed ID: 32488626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of TNF-Inhibitors.
    Atiqi S; Hooijberg F; Loeff FC; Rispens T; Wolbink GJ
    Front Immunol; 2020; 11():312. PubMed ID: 32174918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal.
    Garlits J; McAfee S; Taylor JA; Shum E; Yang Q; Nunez E; Kameron K; Fenech K; Rodriguez J; Torri A; Chen J; Sumner G; Partridge MA
    AAPS J; 2023 Apr; 25(3):37. PubMed ID: 37016171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics.
    Dubiel EA; Fülöp T; Vigier S; Vermette P
    Anal Bioanal Chem; 2017 Dec; 409(30):7153-7167. PubMed ID: 29026983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
    Gehin JE; Goll GL; Brun MK; Jani M; Bolstad N; Syversen SW
    BioDrugs; 2022 Nov; 36(6):731-748. PubMed ID: 36315391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Method validation of a bridging immunoassay in combination with acid-dissociation and bead treatment for detection of anti-drug antibody.
    Du J; Yang Y; Zhu L; Wang S; Yu C; Liu C; Long C; Chen B; Xu G; Zou L; Wang L
    Heliyon; 2023 Mar; 9(3):e13999. PubMed ID: 36915535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
    Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
    J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naïve Subjects.
    Liao K; Derbyshire S; Wang KF; Caucci C; Tang S; Holland C; Loercher A; Gunn GR
    AAPS J; 2018 Mar; 20(3):51. PubMed ID: 29549534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical considerations for calculation of immunogenicity screening assay cut points.
    Hoffman D; Berger M
    J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.